Farxiga cuts hospitalisation for heart failure or CV death, study shows
AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.
Read More
